JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - Mizuho raised its price target on Insmed (NASDAQ:INSM) to $165.00 from $130.00 on Wednesday, while maintaining an Outperform rating on the stock. The company, now valued at $25.79 billion, has shown remarkable momentum with a 76.71% return year-to-date and is currently trading near its 52-week high of $122.03.
The price target increase follows the U.S. approval of Brinsupri, prompting Mizuho to update its model with revised probability of success and pricing assumptions across multiple indications and geographies.
Mizuho has increased its peak-year sales estimate for Brinsupri to $7.7 billion in non-cystic fibrosis bronchiectasis (NCFBE), up from a previous estimate of $6.6 billion, and $10.8 billion overall compared to $9.4 billion previously.
The 27% increase in price target reflects Mizuho’s confidence in Insmed’s ability to execute the Brinsupri commercial launch, despite acknowledging that commercial launches can be challenging.
Mizuho’s new price target represents approximately 35% upside potential from current levels, with the firm expecting momentum in Insmed shares to continue as Street estimates move higher.
In other recent news, Insmed has achieved a significant milestone with the FDA’s approval of Brinsupri (brensocatib), marking it as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB). This approval allows the drug to be available in both 10 mg and 25 mg doses for patients aged 12 and older. Following this development, several financial firms have adjusted their outlook on Insmed. Wells Fargo raised its price target to $140 while maintaining an Overweight rating, noting the drug’s pricing at the high end of previous guidance. UBS also increased its price target to $140, maintaining a Buy rating, and highlighted the drug’s broad label without significant warnings or monitoring requirements. Jefferies raised its price target to $148, citing the approval as a "best-case scenario" for the untapped bronchiectasis market. Conversely, Morgan Stanley downgraded Insmed to Equalweight, despite raising its price target to $126, acknowledging the approval as a significant step in the company’s growth in rare lung diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.